Search Results - treatment

35 Results

Sort By:

Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers

This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and...

Published: 7/25/2024 | Inventor(s): Jung-hee Woo, David Neville, Arthur Frankel, Andrew Thorburn, Michael Glode, Thomas Flaig

Keywords(s): cancers, DT390-EGF, EGF, Fusion, POSITIVE, Protein, RECEPTOR, treatment, VCXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Therapeutics

Diagnosis and Treatment of Pediatric Acute Neurologic Syndrome with Antineuronal Antibodies

The invention is a panel of five tests of patient sera for immune responses that may attack the brain and lead to the characteristic symptoms of pediatric acute neurologic syndrome (PANS). PANS is a condition defined by a sudden onset of obsessive-compulsive symptoms, eating restrictions, and other cognitive and/or behavioral symptoms. Currently, the...

Published: 7/25/2024 | Inventor(s): Susan Swedo, Christine Kirvan, Madelein Cunningham

Keywords(s): ACUTE, antibodies, Antineuronal, Diagnosis, Listed LPM Greene as of 4/15/2015, Neurologic, pediatric, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Syndrome, treatment, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XAXXXX, XCXXXX

Category(s): TherapeuticArea > Psychiatry/Mental Health, TherapeuticArea > Neurology, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, ResearchProducts > Antibodies

Synthetic Genes for the Treatment of Propionic Acidemia (PA) Caused by Mutations in Propionyl-coA Carboxylase Alpha (PCCA)

Propionic acidemia (PA) is an autosomal recessive metabolic disorder caused by mutations in either PCCA or PCCB. The products of these genes form the alpha and beta subunits of the enzyme propionyl-Co A carboxylase (PCC), a critically important mitochondrial enzyme involved in the catabolism of branched chain amino acids. NHGRI scientist have developed...

Published: 7/25/2024 | Inventor(s): Randy Chandler, Charles Venditti

Keywords(s): Acidemia, ALPHA, Carbox, CAUSED, GENES, Lase, Mutations, PA, Pcca, Propionic, PropionylcoA, Synthetic, treatment, VPXXXX, WIXXXX, XEXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Cardiology, TherapeuticArea > Oncology, TherapeuticArea > Ophthalmology, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Research Materials

High Concentration Methylcobalamin (Me-Cbl) or Combination of Methyl- and Hydroxocobalamin (Me/OH-Cbl) for the Treatment of Cobalamin C Deficiency and Related Disorders

Cobalamin C deficiency (cblC), caused by mutations in MMACHC, is the most common inborn error of intracellular vitamin B12 metabolism. NHGRI scientist have generated a number of Mmachc knockout mouse models. The cblC mice present with early lethality, recapitulate the neurological phenotype seen in patients, and have enabled proof of concept testing...

Published: 7/25/2024 | Inventor(s): Jennifer Sloan, Eirini (Irini) Manoli, Charles Venditti

Keywords(s): C, Cobalamin, Combination, Concentration, DEFICIENCY, DISORDERS, High, Hydroxocobalamin, Me/OH-Cbl, Me-Cbl, Methyl-, Methylcobalamin, RELATED, treatment, VPXXXX, WKXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Cardiology, TherapeuticArea > Infectious Disease, TherapeuticArea > Ophthalmology, TherapeuticArea > Oncology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental

Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer Treatment

This technology includes the use of pyridines for anticancer treatment. A common feature of cancer cells is a high level of reactive oxygen species with a concomitant increase of two antioxidative systems to combat the toxicity: the glutathione and thioredoxin systems. Inhibiting either, or both, of these systems is a promising avenue to target cancer...

Published: 7/25/2024 | Inventor(s): Ajit Jadhav, Diane Luci, Thomas Dexheimer, Anton Simeonov, Nathan Coussens, David Maloney

Keywords(s): CANCER, Novel, PYRIDINES, Their, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): Application > Research Materials, TherapeuticArea > Oncology, Application > Therapeutics

Development of a Therapy for the Treatment of Zellweger Spectrum Disorder

This technology includes a method for selecting a therapeutic effective amount of one of two compounds (including naltriben and naltrin) for the treatment of Zellweger Spectrum Disorder (ZSD), or any disease associated with peroxisome dysfunction. The compounds were identified using a cell-image based high-content screening (HCS) assay to identify small...

Published: 7/25/2024 | Inventor(s): Patricia Dranchak, James Inglese

Keywords(s): DEVELOP, DISORDER, Spectrum, THERAPY, TOOLS, treatment, VEXXXX, WIXXXX, WKXXXX, Zellweger

Category(s): TherapeuticArea > Neurology, Application > Therapeutics, Application > Research Materials

Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection

This invention includes the discovery and use of a group of CDK inhibitors that were found during a drug repurposing screen designed to find compounds that inhibit Zika virus caused cell death. The identified CDK inhibitors have all previously been used in clinical trials for other diseases, potentially reducing the long time course needed for new drug...

Published: 7/25/2024 | Inventor(s): Ruili Huang, Miao Xu, Wenwei Huang, Hengli Tang, Emily Lee, Cheng YiChen, Yi Zhou, Hongjun Song, Guo-Li Ming, Zhexing Wen, Wei Zheng

Keywords(s): CDK, Infection, Inhibitors, Repurposing, treatment, VEXXXX, virus, VLXXXX, WIXXXX, WKXXXX, Zika

Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Research Materials

The Use of Emetine for the Treatment of SARS-CoV-2 Infection

This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues...

Published: 7/25/2024 | Inventor(s): Mark Henderson, Juan Marugan, Andreas Dulcey Gracia, Xin Hu, Marc Ferrer-Alegre, Noel Southall

Keywords(s): Emetine, Infection, SARS-CoV-2, treatment, VLXXXX, WIXXXX, WKXXXX

Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Research Materials

Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection

This technology includes the use of two related compounds, Emetine and Cephaeline, as a potent inhibitor of the Zika virus (ZIKV). Emetine and it's analog Cephaeline were identified in a high-throughput assay aimed at identifying anti-ZIKV compounds. Both Emetine and Cephaeline are potent inhibitors of ZIKV infection in cell culture, and Emeline is...

Published: 7/25/2024 | Inventor(s): Emily Lee, Wei Zheng, Miao Xu, Ruili Huang, Shu Yang, Wenwei Huang, Khalida Shamim, Hao Li, Hengli Tang

Keywords(s): compounds, Emetine, Flavivirus, Infection, Prevention, treatment, VLXXXX, WIXXXX, WKXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Research Materials

Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers

The technology includes the creation of a high-throughput assay and the identification and use of small molecules that inhibit the SIX/EYA interaction as a treatment for cancer. The Eya proteins are phosphatases that form a complex and are activated by the Six family of homeobox transcription factors. The interaction of Eya and Six mediates breast cancer...

Published: 7/25/2024 | Inventor(s): Marc Ferrer-Alegre, Xin Hu, Juan Marugan, Lesley Mathews, Heide Ford, Melanie Blevins, Rebecca Mull, Rui Zhao

Keywords(s): cancers, Identification, Identifying, Inhibitors, INTERACTION, Listed LPM Vathyam as of 4/15/2015, Method, MOLECULE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SIX/EYA, Small, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology

1 2 3 4